ArticleCancer research2019
MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 69 citations in OpenAlex.
- The roles of chromatin remodeling and 3D genome organization in cancers: from mechanistic insights to emerging treatment options.Molecular cancer · 2026Review
- TP53-META, a meta-analysis tool for comparative transcriptomics of TP53 dependency: examples from target silencing and liver fibrosis.BMC bioinformatics · 2026Article
- Paediatric Therapeutic Development Workshop on rhabdoid tumours.British journal of cancer · 2026Review
- The future of targeted therapies for pediatric central nervous system tumors.Neuro-oncology advances · 2026Review
- PHIP suppresses NuRD to enable the growth of SWI/SNF-mutant cancers.Nature communications · 2026Article
- p53 increases phospholipid headgroup scavenging in senescence.Nature cell biology · 2026Article
- Targeting CDK11 in Rhabdoid Tumor of the Kidney.Cancers · 2026Article
- Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors.Neuro-oncology pediatrics · 2026Article
- Dependence on Mdm2 for Mdm4 inhibition of p53 activity.Cancer letters · 2025Article
- Image-guided targeting of mitochondrial metabolism sensitizes pediatric malignant rhabdoid tumors to low-dose radiotherapy.Science advances · 2025Article
- Epstein-Barr virus nuclear antigen 1 (EBNA1) increases the expression levels of MDM2 and MDM4 genes in HeLa cells: a review on MDM2 and MDM4 roles in cancer.BMC research notes · 2025Article
- Small glycomimetic antagonists of the cytomegalovirus glycoprotein UL141 prevent binding to TRAIL death receptor.The Journal of biological chemistry · 2025Article
- Elevated p16Ink4a Expression Enhances Tau Phosphorylation in Neurons Differentiated From Human-Induced Pluripotent Stem Cells.Aging cell · 2025Article
- Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type.iScience · 2025Article
- SMARCB1/INI1-deficient lung cancer with lymph node metastasis: a case report and literature review.AME case reports · 2025Article
- Chromatin remodellers as therapeutic targets.Nature reviews. Drug discovery · 2024Review
- Developmental origins shape the paediatric cancer genome.Nature reviews. Cancer · 2024Review
- Modeling human brain rhabdoid tumor by inactivating tumor suppressor genes in induced pluripotent stem cells.Bioactive materials · 2024Article
- Article
- Children's Oncology Group's 2023 blueprint for research: Renal tumors.Pediatric blood & cancer · 2023Article
Corrections and comments
- Commented on by
Authors and funding
28 authors at 3 institutions in 1 country.
Thomas P HowardDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.ORCID 0000-0002-3438-2831
Taylor E ArnoffDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
Melinda R SongDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
Andrew O GiacomelliDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-2109-0458
Xiaofeng WangDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
Andrew L HongDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.ORCID 0000-0003-0374-1667
Neekesh V DhariaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.ORCID 0000-0001-5048-067X
Su WangDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts.
Francisca VazquezBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0002-2857-4685
Minh-Tam PhamDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
Ann M MorganDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
Franziska WachterDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
Gregory H BirdDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
Guillaume KugenerBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Elaine M OberlickDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.ORCID 0000-0003-2809-0506
Matthew G ReesBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0002-2987-7581
Hong L TivExperimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Justin H HwangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Katherine H WalshDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
April CookDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
John M Krill-BurgerBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0001-9614-4671
Aviad TsherniakBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0002-3797-1877
Prafulla C GokhaleExperimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Peter J ParkDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-9378-960X
Kimberly StegmaierDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
Loren D WalenskyDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
William C HahnDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Charles.roberts@stjude.org william_hahn@dfci.harvard.edu.
Charles W M RobertsDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts. Charles.roberts@stjude.org william_hahn@dfci.harvard.edu.
Broad Institute · USDana-Farber Cancer Institute · USHarvard University · US
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MMedical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MMolecular, Cellular, & Developmental Dynamics PhD ProgramT32GM007226 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI VAN VACTOR, DAVID L. · 1985 to 2021
$14.4MDissecting and Targeting Deregulated Mitochondrial Apoptosis in Human CancerR35CA197583 · NCI · DANA-FARBER CANCER INST · PI Loren David Walensky · 2015 to 2026
$12.5MResearch Training in Pediatric OncologyT32CA136432 · NCI · DANA-FARBER CANCER INST · PI SCOTT A ARMSTRONG · 2009 to 2026
$7.9MThe Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8MTHE FUNCTION OF SNF5 (SMARCB1), AN EPIGENETIC TUMOR SUPPRESSORR01CA113794 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 2005 to 2026
$7.8MIntegrating Transforming Approaches to Identify and Target New Vulnerabilities in CancerR35CA210030 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2016 to 2022
$7.3MRole of the SWI/SNF complex in tumor suppressionR01CA172152 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 2013 to 2026
$5.1MStapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human CancerR50CA211399 · NCI · DANA-FARBER CANCER INST · PI Gregory Howard Bird · 2016 to 2026
$3.2MRole of SNF5 in regulating SWI/SNF complex assembly & targeting in rhabdoid tumorR00CA197640 · NCI · DARTMOUTH COLLEGE · PI WANG, XIAOFENG · 2018 to 2020
$713kNCI NIH HHS F30 CA221087NCI NIH HHS P30 CA021765NCI NIH HHS P50 CA101942NCI NIH HHS R00 CA197640NCI NIH HHS R01 CA113794NCI NIH HHS R01 CA172152NCI NIH HHS R35 CA197583NCI NIH HHS R35 CA210030NCI NIH HHS R50 CA211399NCI NIH HHS T32 CA136432NCI NIH HHS U01 CA176058NIGMS NIH HHS T32 GM007226NIGMS NIH HHS T32 GM007753
Abstract
Malignant rhabdoid tumors (MRT) are highly aggressive pediatric cancers that respond poorly to current therapies. In this study, we screened several MRT cell lines with large-scale RNAi, CRISPR-Cas9, and small-molecule libraries to identify potential drug targets specific for these cancers. We discovered
Indexed as
AnimalsAntineoplastic AgentsApoptosisCell Cycle ProteinsCell ProliferationCRISPR-Cas SystemsFemaleGene Expression Regulation, NeoplasticHumansMiceMice, NudeProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2Rhabdoid TumorSMARCB1 ProteinTumor Cells, CulturedAntineoplastic AgentsCell Cycle ProteinsMDM2 protein, humanMDM4 protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2SMARCB1 ProteinSMARCB1 protein, humanTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.